John Zajecka to Antidepressive Agents, Second-Generation
This is a "connection" page, showing publications John Zajecka has written about Antidepressive Agents, Second-Generation.
Connection Strength
1.379
-
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. J Clin Psychiatry. 2002 Aug; 63(8):709-16.
Score: 0.207
-
Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:42-7.
Score: 0.199
-
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000 May 18; 342(20):1462-70.
Score: 0.177
-
Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol. 1998 Jun; 18(3):193-7.
Score: 0.155
-
The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry. 1996; 57 Suppl 2:10-4.
Score: 0.131
-
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
Score: 0.089
-
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry. 2007 Dec 15; 62(12):1371-9.
Score: 0.074
-
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007 Aug; 68(8):1246-56.
Score: 0.073
-
A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
Score: 0.064
-
Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry. 2003 Oct 15; 54(8):806-17.
Score: 0.056
-
Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol. 2003 May; 18(3):151-6.
Score: 0.054
-
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry. 2002 May; 63(5):434-41.
Score: 0.051
-
Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry. 2002; 63 Suppl 1:32-41.
Score: 0.050